Premium
Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross‐sectional comparison with procollagen‐3 N‐terminal peptide (P3 NP )
Author(s) -
Voort E.A.M.,
Wakkee M.,
VeldtKok P.,
Darwish Murad S.,
Nijsten T.
Publication year - 2017
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15220
Subject(s) - medicine , psoriatic arthritis , rheumatoid arthritis , psoriasis , gastroenterology , arthritis , procollagen peptidase , immunology
Summary Background The enhanced liver fibrosis ( ELF ) test has been introduced to screen, diagnose and/or monitor liver conditions in large groups of patients with liver diseases. It has not been used in inflammatory skin or joint diseases. Objectives To evaluate the distribution of the ELF test, apply existing cut‐offs for hepatic patients and healthy controls, and compare it with the procollagen‐3 N‐terminal peptide (P3 NP ) test in patients with psoriasis ( PSO ), psoriatic arthritis (PsA) and rheumatoid arthritis ( RA ), and controls. Methods In total, 531 patients were included. Demographic, lifestyle and disease‐specific data were collected. ELF and P3 NP tests were performed. Results Prevalence of an increased ELF score (> 11) and P3 NP was highest in patients with RA (7·7% and 6·1%, respectively) followed by patients with PSO (1·7% and 5·2%, respectively) and PsA (0·7% and 1·3%, respectively). Mean ± SD ELF scores for PSO , PsA and RA were, respectively, 9·09 ± 0·86, 8·96 ± 0·76 and 9·55 ± 1·04. All subgroups with moderate‐to‐severe disease severity had higher (> 9·8) ELF scores ( PSO 27·0% vs. 18·3%; PsA 19·2% vs. 12%; RA 45·8% vs. 30·5%) and P3 NP values. Distribution of the ELF score was smaller than the P3 NP value [mean ± SD : 9·15 ± 0·92 (range 6·53–13·05) vs. 8·37 ± 4·30 (range 0·53–63·88)]. Conclusions ELF score and P3 NP are elevated in PSO , PsA and RA . ELF may be superior to P3 NP alone, but further research should be done to validate the ELF test in determining susceptibility for developing liver fibrosis in PSO , PsA and RA .